[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
    "url": "https://finnhub.io/api/news?id=f7d1cdb09ab9ee10265c577baf474f32a19fadf1143eff3e933cb71089d94a29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767818827,
      "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
      "id": 138033033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
      "url": "https://finnhub.io/api/news?id=f7d1cdb09ab9ee10265c577baf474f32a19fadf1143eff3e933cb71089d94a29"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final […]",
    "url": "https://finnhub.io/api/news?id=03cf73ce3b4cac8dc68d82c1e3eeab5742fb57e9432fb8add6fabd30d6b2bdf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767817999,
      "headline": "Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs",
      "id": 138033055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final […]",
      "url": "https://finnhub.io/api/news?id=03cf73ce3b4cac8dc68d82c1e3eeab5742fb57e9432fb8add6fabd30d6b2bdf4"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Imaavy posts win in Phase II SLE trial",
    "summary": "Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if approved.",
    "url": "https://finnhub.io/api/news?id=7076e403195ee87ee8e5ed60d6085c3626f09bd905b92b360287d541e99c31e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767807748,
      "headline": "J&J’s Imaavy posts win in Phase II SLE trial",
      "id": 138033056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if approved.",
      "url": "https://finnhub.io/api/news?id=7076e403195ee87ee8e5ed60d6085c3626f09bd905b92b360287d541e99c31e0"
    }
  },
  {
    "ts": null,
    "headline": "Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033 Featuring L'Oreal, P&G, Oriflamme, Unilever, Estee Lauder Company, Johnson & Johnson",
    "summary": "Facial Skincare Market Facial Skincare Market Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The \"Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033\" has been added to ResearchAndMarkets.com's offering. The worldwide facial skincare market is anticipated to hit US$ 158.63 billion in 2033, increasing from US$ 98.56 billion in 2024, growing at a CAGR of 5.43% during 2025-2033. Increased consumer knowledge, the need for anti-aging, and new developmen",
    "url": "https://finnhub.io/api/news?id=96fd2e4752c89b3f2d3456078b200e54629b0b2b4b5fe873095f6ecf86df112a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767806220,
      "headline": "Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033 Featuring L'Oreal, P&G, Oriflamme, Unilever, Estee Lauder Company, Johnson & Johnson",
      "id": 138033057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Facial Skincare Market Facial Skincare Market Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The \"Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033\" has been added to ResearchAndMarkets.com's offering. The worldwide facial skincare market is anticipated to hit US$ 158.63 billion in 2033, increasing from US$ 98.56 billion in 2024, growing at a CAGR of 5.43% during 2025-2033. Increased consumer knowledge, the need for anti-aging, and new developmen",
      "url": "https://finnhub.io/api/news?id=96fd2e4752c89b3f2d3456078b200e54629b0b2b4b5fe873095f6ecf86df112a"
    }
  },
  {
    "ts": null,
    "headline": "JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus",
    "summary": "J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.",
    "url": "https://finnhub.io/api/news?id=fc18bbe27dae526876984972cfe25d1bd6fff17fc4a473133aaa7f2610b8cf91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767804540,
      "headline": "JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus",
      "id": 138033058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.",
      "url": "https://finnhub.io/api/news?id=fc18bbe27dae526876984972cfe25d1bd6fff17fc4a473133aaa7f2610b8cf91"
    }
  },
  {
    "ts": null,
    "headline": "Should You Chase the Rally in Alumis Stock Today?",
    "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
    "url": "https://finnhub.io/api/news?id=f52f15084633e6f237aa4a582f2f9d56fa92ca19d97c0378296092ad3d2c5315",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803749,
      "headline": "Should You Chase the Rally in Alumis Stock Today?",
      "id": 138033059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
      "url": "https://finnhub.io/api/news?id=f52f15084633e6f237aa4a582f2f9d56fa92ca19d97c0378296092ad3d2c5315"
    }
  },
  {
    "ts": null,
    "headline": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
    "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
    "url": "https://finnhub.io/api/news?id=2c397c3ece6f139d071a5da726d71c7b7b4b3be02a2f027079c983b3bd1cc5da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803640,
      "headline": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
      "id": 138033060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
      "url": "https://finnhub.io/api/news?id=2c397c3ece6f139d071a5da726d71c7b7b4b3be02a2f027079c983b3bd1cc5da"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=8f5a9e4562f0dabf8c46a68f4abea45951a2ac174311b501df8c1c657039a12f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767794404,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138027088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=8f5a9e4562f0dabf8c46a68f4abea45951a2ac174311b501df8c1c657039a12f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline",
    "summary": "AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=f6b040665acd6d6b6a6c4a27817b163bd750a5f3f4f7c579932d640034bc74e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767792780,
      "headline": "Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline",
      "id": 138027089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=f6b040665acd6d6b6a6c4a27817b163bd750a5f3f4f7c579932d640034bc74e2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration",
    "summary": "NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.",
    "url": "https://finnhub.io/api/news?id=8fdf5c8d28cf22c0cae8662c7f6ca12a8f7dfc8988baa78931912547174f1c12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790800,
      "headline": "Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration",
      "id": 138027090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.",
      "url": "https://finnhub.io/api/news?id=8fdf5c8d28cf22c0cae8662c7f6ca12a8f7dfc8988baa78931912547174f1c12"
    }
  },
  {
    "ts": null,
    "headline": "Update: Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
    "summary": "(Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri",
    "url": "https://finnhub.io/api/news?id=e5c77a2fe7091981dd53185666bec5831fb972f3f299051ef9ee72dd1795f29a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767780436,
      "headline": "Update: Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
      "id": 138025813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri",
      "url": "https://finnhub.io/api/news?id=e5c77a2fe7091981dd53185666bec5831fb972f3f299051ef9ee72dd1795f29a"
    }
  },
  {
    "ts": null,
    "headline": "The Smartest Dividend Stocks to Buy With $3,000 Right Now",
    "summary": "It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's.",
    "url": "https://finnhub.io/api/news?id=8813f95d6dfbd39436391ce1368d9bcf83557878d7fdae6fbe707397d47c17dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767776100,
      "headline": "The Smartest Dividend Stocks to Buy With $3,000 Right Now",
      "id": 138025814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's.",
      "url": "https://finnhub.io/api/news?id=8813f95d6dfbd39436391ce1368d9bcf83557878d7fdae6fbe707397d47c17dc"
    }
  },
  {
    "ts": null,
    "headline": "Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
    "summary": "Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi",
    "url": "https://finnhub.io/api/news?id=c93fa9c0158f85e0cd9a915d7eb39afb2c20ee091a54a1d292c654d0624fc0a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767776014,
      "headline": "Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
      "id": 138025815,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi",
      "url": "https://finnhub.io/api/news?id=c93fa9c0158f85e0cd9a915d7eb39afb2c20ee091a54a1d292c654d0624fc0a3"
    }
  },
  {
    "ts": null,
    "headline": "Stereotaxis wins FDA approval for robotically navigated ablation catheter",
    "summary": "Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.",
    "url": "https://finnhub.io/api/news?id=b812fff5ec1fa3759457eb1636ae4c637870c8e793d31a8cdf47a530a5966cef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767761398,
      "headline": "Stereotaxis wins FDA approval for robotically navigated ablation catheter",
      "id": 138027091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.",
      "url": "https://finnhub.io/api/news?id=b812fff5ec1fa3759457eb1636ae4c637870c8e793d31a8cdf47a530a5966cef"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) Still Attractive After A 44% One Year Share Price Gain",
    "summary": "If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk through what the current price might be implying about the company. The stock last closed at US$204.79, with returns of 1.4% over 30 days and 44.3% over 1 year, which may have changed how some investors think about both its potential and its risks. Over the past year, Johnson & Johnson has remained in focus as a large healthcare name. Investors have been watching how it...",
    "url": "https://finnhub.io/api/news?id=43377e4a452b111db43ba7a6fad9c7cb1593f70766d6c6be98ebc0fd96f89bbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767748098,
      "headline": "Is Johnson & Johnson (JNJ) Still Attractive After A 44% One Year Share Price Gain",
      "id": 138022709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk through what the current price might be implying about the company. The stock last closed at US$204.79, with returns of 1.4% over 30 days and 44.3% over 1 year, which may have changed how some investors think about both its potential and its risks. Over the past year, Johnson & Johnson has remained in focus as a large healthcare name. Investors have been watching how it...",
      "url": "https://finnhub.io/api/news?id=43377e4a452b111db43ba7a6fad9c7cb1593f70766d6c6be98ebc0fd96f89bbf"
    }
  }
]